Related Experiment Video
Updated: Apr 20, 2026
12:02
Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
14.7K
PTEN inhibitors: an evaluation of current compounds
Laura Spinelli1, Yvonne E Lindsay2, Nicholas R Leslie1
1Institute of Biological Chemistry, Biophysics and Bioengineering, Nasmyth Building, Heriot Watt University, Edinburgh, EH14 4AS, UK; Division of Cell Signalling and Immunology, College of Life Sciences, University of Dundee, Dow Street, Dundee, DD1 5EH, UK.
Advances in Biological Regulation
|December 3, 2014
Summary
Investigating PTEN inhibitors revealed broad enzyme inhibition, particularly by vanadate compounds. Bisperoxovanadates showed poor PTEN inhibition with reducing agents like glutathione.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Small molecule enzyme inhibitors, including phosphatases, are vital research tools and therapeutics.
- PTEN (phosphatase and tensin homolog) is a tumor suppressor; its inhibition was previously concerning for cancer risk.
- Emerging evidence suggests short-term PTEN inhibition may benefit conditions like nerve injury, renewing research interest.
Purpose of the Study:
- To investigate the inhibitory effects of four PTEN inhibitors: bpV(phen), bpV(pic), VO-OHpic, and SF1670.
- To compare the inhibitory activity of these compounds against PTEN and three related enzymes: SHP1, INPP4A, and INPP4B.
- To assess the impact of reducing agents on PTEN inhibition by these compounds.
Main Methods:
- Enzyme inhibition assays were performed using PTEN, SHP1, INPP4A, and INPP4B.
- Four PTEN inhibitors (bpV(phen), bpV(pic), VO-OHpic, SF1670) were tested.
- Inhibition was evaluated in the presence and absence of reducing agents, specifically glutathione.
Main Results:
- All tested compounds inhibited multiple enzymes, not just PTEN.
- Three vanadate compounds (bpV(phen), bpV(pic), VO-OHpic) showed inhibition of PTEN and related enzymes that was similar or more potent than PTEN inhibition.
- Bisperoxovanadate compounds exhibited poor PTEN inhibition in the presence of reducing agents like glutathione.
Conclusions:
- Available PTEN inhibitors demonstrate off-target effects, inhibiting multiple related enzymes.
- Vanadate-based inhibitors, particularly bisperoxovanadates, show complex inhibition profiles influenced by cellular redox conditions.
- Further research is needed to develop selective PTEN inhibitors and understand their therapeutic potential, considering off-target effects and reducing agent interference.
More Related Videos
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
47
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
47
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:29Pharmacogenomics: Identification of New Drug Targets
104
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
104
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
583
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
583
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
626
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
626